India’s first global CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL), a kind of blood cancer that affects ...

Yescarta – a CD19-directed genetically modified autologous T-cell immunotherapy investigated in the ZUMA-1 trial – is the first chimeric antigen receptor (CAR) T-cell therapy recommended for ...

Scripps Research Institute spin-out Calibr's lead candidate combines CLBR001 cells – billed as a "universal" CAR-T because they are not targeted at a specific antigen – and companion antibody ...

Larger studies are needed to assess efficacy, but early data suggest this approach could offer a less toxic alternative to CAR-T cell therapies that are approved by the Food and Drug ...

Copyright: © 2025 Elsevier Ltd. Published by Elsevier Ltd. CAR T-cell therapies have revolutionised treatment of many diseases, but their expense means many patients ...

The therapy can cost anywhere between $350,000 and $700,000 globally. While Immuneel has brought it down to about ₹51 lakh to ...

H3K27M-mutated diffuse midline gliomas (DMGs) are lethal cancers of the central nervous system (CNS). They affect mainly children and young adults, and are a leading cause of childhood-cancer ...

Researchers have discovered a three-drug combination that enhances the generation of CAR-T ... cell subset responsible for long-term persistence." Dotti and Yang Xu, PhD, are the paper's ...

A study published in Science Advances shares new insights into how two of the most common types of chimeric antigen receptor (CAR) T cells kill cancer. Investigators from Baylor College of ...

CAR T cells show contrasting approaches to killing cancer, with one sprinting for fast action and the other collaborating for endurance. Scientists are now focusing on adapting these cells to outsmart ...

Credit: Mongkolchon Akesin/Shutterstock. Umoja Biopharma has announced the closing of an oversubscribed $100m Series C financing round, which will enable the company to progress its in vivo chimeric ...